Treatment of lung cancer

Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer

Tuesday, January 19, 2021 - 2:35pm

(NASDAQ: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced an agreement on a Phase 1b clinical trial with City of Hope , a world-renowned independent cancer research and treatment center.

Key Points: 
  • (NASDAQ: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced an agreement on a Phase 1b clinical trial with City of Hope , a world-renowned independent cancer research and treatment center.
  • The trial will assess the combination of Lixtes first-in-class protein phosphatase inhibitor LB-100 with a standard regimen for untreated, extensive stage-disease small cell lung cancer (ED-SCLC).
  • John S. Kovach, M.D., Lixte founder and chief executive officer, said Small cell lung cancer (SCLC) comprises approximately 15% of all lung cancers worldwide with about 30,000 new cases annually in the US.
  • We look forward to working with Lixte on this important trial that we hope will make more therapeutic options available for patients with small cell lung cancer.

China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer

Thursday, January 14, 2021 - 4:00am

This is the third approval in China for tislelizumab, and its first in a lung cancer indication.

Key Points: 
  • This is the third approval in China for tislelizumab, and its first in a lung cancer indication.
  • Tislelizumab is being investigated in a broad clinical program, including five Phase 3 trials in lung cancer indications.
  • We are grateful to have a new treatment available in the front-line setting for patients with advanced squamous non-small cell lung cancer, said Jie Wang, M.D., Ph.D., National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.
  • The China National Medical Products Administration (NMPA) has granted tislelizumab full approval for first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy.

Global Non-Small Cell Lung Cancer Drug Forecast and Market Analysis 2019-2020 & 2029 - 29 Late-stage Pipeline Agents are Going to Enter the NSCLC Market

Wednesday, January 13, 2021 - 8:15pm

DUBLIN, Jan. 13, 2021 /PRNewswire/ -- The "Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 13, 2021 /PRNewswire/ -- The "Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.
  • Non-small cell lung cancer (NSCLC) is currently the most common cancer in the world and is the leading cause of cancer mortality in men and women.
  • 29 late-stage pipeline agents are going to enter the NSCLC market from 2019 onwards.
  • Topline NSCLC market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer

Wednesday, January 13, 2021 - 2:00pm

This production provides supply of REQORSA for our two upcoming Acclaim clinical trials and advances our mission to develop innovative new treatments for non-small cell lung cancer patients greatly in need of effective therapy options.

Key Points: 
  • This production provides supply of REQORSA for our two upcoming Acclaim clinical trials and advances our mission to develop innovative new treatments for non-small cell lung cancer patients greatly in need of effective therapy options.
  • The Company also reported the completion of the manufacturing scale-up for the clinical-grade production of REQORSA , subject to final testing that was underway.
  • From there, REQORSA supply will be delivered to the clinical trial sites pending FDA clearance to commence the clinical trials.
  • The Companys lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC).

Global Non-Small Cell Lung Cancer Drug Forecast and Market Analysis to 2029 - ResearchAndMarkets.com

Tuesday, January 12, 2021 - 12:47pm

The "Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.
  • Non-small cell lung cancer (NSCLC) is currently the most common cancer in the world and is the leading cause of cancer mortality in men and women.
  • Of total lung cancer incident cases, approximately 85% are the NSCLC subtype.
  • Since the last global market forecast (2015-2025), there have been significant changes in the treatment of patients with advanced disease, particularly in the metastatic setting.

Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Monday, November 30, 2020 - 7:05pm

Genprex, Inc. (Genprex or the Company) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is pleased to announce it has commenced clinical trial site recruitment for its upcoming Acclaim-1 clinical trial for the treatment of non-small cell lung cancer (NSCLC).

Key Points: 
  • Genprex, Inc. (Genprex or the Company) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is pleased to announce it has commenced clinical trial site recruitment for its upcoming Acclaim-1 clinical trial for the treatment of non-small cell lung cancer (NSCLC).
  • Genprex received U.S. Food and Drug Administration (FDA) Fast Track Designation for its Acclaim-1 patient population in January of 2020.
  • We look forward to working with leading clinical investigators who will help drive our mission to bring forth a treatment for advanced lung cancer patients.
  • The Companys lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC).

eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer® (SU2C) Canada

Thursday, November 12, 2020 - 1:12pm

The study [ NCT04261218 ] is funded through Stand Up To Cancer (SU2C) Canada.

Key Points: 
  • The study [ NCT04261218 ] is funded through Stand Up To Cancer (SU2C) Canada.
  • Tomivosertib is an oral, small molecule inhibitor of MNK1/2 that enhances T cell killing of tumors, delays T cell exhaustion and enhances T cell memory.
  • Paclitaxel is a chemotherapy agent used to treat multiple tumor types, including breast cancer.
  • Tomivosertib is expected to enter KICKSTART, eFFECTORs randomized, placebo-controlled, double-blind Phase 2 study in non-small lung cancer (NSCLC) in combination with pembrolizumab, in Q4 2020.

Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer To Stop for Futility and Patients to Discontinue...

Monday, November 9, 2020 - 9:10pm

KEYTRUDA monotherapy remains a standard of care for the treatment of certain patients with metastatic non-small cell lung cancer whose tumors express PD-L1.

Key Points: 
  • KEYTRUDA monotherapy remains a standard of care for the treatment of certain patients with metastatic non-small cell lung cancer whose tumors express PD-L1.
  • Merck has an extensive clinical development program in lung cancer and is advancing multiple registration-enabling studies with KEYTRUDA in combination with other treatments and as monotherapy.
  • Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all cases.
  • KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.

Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

Monday, November 9, 2020 - 1:00pm

At the time of analysis, 123 patients with advanced cancers had been treated with cosibelimab and were evaluable for safety.

Key Points: 
  • At the time of analysis, 123 patients with advanced cancers had been treated with cosibelimab and were evaluable for safety.
  • Cosibelimab appeared to be safe and well-tolerated with a potentially favorable safety profile as compared to anti-PD-1 therapies currently available.
  • A copy of the poster presentation is available on the Publications page of the Pipeline section of Checkpoints website, www.checkpointtx.com .
  • According to the American Cancer Society, it is estimated that more than 228,000 Americans will be diagnosed with lung cancer in 2020, and non-small cell lung cancer accounts for 80-85% of all lung cancers.

Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer

Thursday, October 29, 2020 - 12:16pm

We are very pleased to receive FDAs conditional acceptance of our proprietary name, REQORSA, which is a necessary step toward being able to market our lead drug candidate for non-small cell lung cancer, said Rodney Varner, President and Chief Executive Officer of Genprex.

Key Points: 
  • We are very pleased to receive FDAs conditional acceptance of our proprietary name, REQORSA, which is a necessary step toward being able to market our lead drug candidate for non-small cell lung cancer, said Rodney Varner, President and Chief Executive Officer of Genprex.
  • Final approval of the REQORSA brand name is conditional on FDA approval of the product candidate.
  • In January 2020, the FDA granted Fast Track Designation for REQORSA in combination with AstraZenecas Tagrisso for the treatment of non-small cell lung cancer.
  • The Companys lead product candidate, REQORSA immunogene therapy drug (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC).